Key Metrics
H-Index 

2
SJR 

Q4Law

Recommended pre-submission checks
Powered by 

European Pharmaceutical Law Review Journal Specifications
Indexed in the following public directories
Scopus
SJR
| Overview | |
| Publisher | Lexxion Verlagsgesellschaft mbH |
Planning to publish in European Pharmaceutical Law Review ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in European Pharmaceutical Law Review
New Clinical Trial Rules in the EU: A Practical Overview of the Upcoming Regulation
- 1 Jan 2021
- European Pharmaceutical Law Review
‘No-one is Safe Until Everyone is Safe’ – Patent Waiver, Compulsory Licensing and COVID-19
- 1 Jan 2021
- European Pharmaceutical Law Review
Pharmaceutical Advertising in Digital Media: A Danish Perspective
- 1 Jan 2021
- European Pharmaceutical Law Review
Jurisdiction
- 1 Jan 2021
- European Pharmaceutical Law Review
Are You AI’S Favourite? EU Legal Implications of Biased AI Systems in Clinical Genetics and Genomics
- 1 Jan 2021
- European Pharmaceutical Law Review
Does an Initially Authorised Combination Medicinal Product and a Later Authorised Single Component of that Combination Belong to the Same Global Marketing Authorization? - The Tecfidera® Judgment of the General Court in Case T-611/18
- 1 Jan 2021
- European Pharmaceutical Law Review
New Clinical Trial Rules in the EU: A Practical Overview of the Upcoming Regulation
- 1 Jan 2021
- European Pharmaceutical Law Review
‘No-one is Safe Until Everyone is Safe’ – Patent Waiver, Compulsory Licensing and COVID-19
- 1 Jan 2021
- European Pharmaceutical Law Review
Pharmaceutical Advertising in Digital Media: A Danish Perspective
- 1 Jan 2021
- European Pharmaceutical Law Review
Jurisdiction
- 1 Jan 2021
- European Pharmaceutical Law Review
Are You AI’S Favourite? EU Legal Implications of Biased AI Systems in Clinical Genetics and Genomics
- 1 Jan 2021
- European Pharmaceutical Law Review
Does an Initially Authorised Combination Medicinal Product and a Later Authorised Single Component of that Combination Belong to the Same Global Marketing Authorization? - The Tecfidera® Judgment of the General Court in Case T-611/18
- 1 Jan 2021
- European Pharmaceutical Law Review